Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial

Fig. 1

Patient flow diagram, detailing patient disposition of the masitinib 4.5 mg/kg/day and titrated masitinib 6.0 mg/kg/day parallel groups. PBO, placebo; M4.5, masitinib 4.5 mg/kg/day; tPBO, placebo treatment-arm from the titrated dose parallel group; tM6.0, masitinib treatment-arm from the titrated dose parallel group; ITT, intention-to-treat population; SAF, safety population; FAS, full analysis database; GCP, Good Clinical Practice; ADAS-cog, Alzheimer’s Disease Assessment Scale - cognitive subscale; ADCS-ADL, Alzheimer’s Disease Cooperative Study Activities of Daily Living Inventory scale. * See eTable 1 of the Supplemental Information for a summary of reasons for discontinuation before week 24

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193